March 26, 2018 Bio/Pharma/CRO PR/Corporate

Phase III IMpower150 study showed Roche’s TECENTRIQ (atezolizumab) and Avastin (bevacizumab) plus carboplatin and paclitaxel helped people with advanced lung cancer live longer compared to Avastin plus carboplatin and paclitaxel

Basel, 26 March 2018 Phase III IMpower150 study showed Roche’s TECENTRIQ (atezolizumab) and Avastin (bevacizumab) plus carboplatin and paclitaxel helped people with advanced lung cancer live longer compared to Avastin plus carboplatin and paclitaxel These additional data will be submitted to health authorities globally, including the U.S. Food and Drug Administration (FDA) and European Medicines... Read more

March 26, 2018 Bio/Pharma/CRO PR/Corporate

Phase III IMpower150 study showed Roche’s TECENTRIQ (atezolizumab) and Avastin (bevacizumab) plus carboplatin and paclitaxel helped people with advanced lung cancer live longer compared to Avastin plus carboplatin and paclitaxel

Basel, 26 March 2018 Phase III IMpower150 study showed Roche’s TECENTRIQ (atezolizumab) and Avastin (bevacizumab) plus carboplatin and paclitaxel helped people with advanced lung cancer live longer compared to Avastin plus carboplatin and paclitaxel These additional data will be submitted to health authorities globally, including the U.S. Food and Drug Administration (FDA) and European Medicines... Read more

March 22, 2018 Acad, Gov/Utilities

FDA approves Lucentis (ranibizumab injection) 0.3 mg prefilled syringe for diabetic macular edema and diabetic retinopathy

Basel, 22 March 2018 FDA approves Lucentis (ranibizumab injection) 0.3 mg prefilled syringe for diabetic macular edema and diabetic retinopathy First and only prefilled syringe treatment option FDA-approved to treat all forms of diabetic retinopathy in people with or without diabetic macular edema (DME) Diabetic retinopathy is the leading cause of blindness among adults aged... Read more

March 20, 2018 Bio/Pharma/CRO PR/Corporate

Phase III IMpower131 study showed Roche’s TECENTRIQ (atezolizumab) plus chemotherapy (carboplatin and Abraxane) reduced the risk of disease worsening or death in the initial treatment of people with a type of advanced squamous lung cancer

Basel, 20 March 2018 Phase III IMpower131 study showed Roche’s TECENTRIQ (atezolizumab) plus chemotherapy (carboplatin and Abraxane) reduced the risk of disease worsening or death in the initial treatment of people with a type of advanced squamous lung cancer Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMpower131 study met its... Read more

March 20, 2018 Bio/Pharma/CRO PR/Corporate

Phase III IMpower131 study showed Roche’s TECENTRIQ (atezolizumab) plus chemotherapy (carboplatin and Abraxane) reduced the risk of disease worsening or death in the initial treatment of people with a type of advanced squamous lung cancer

Basel, 20 March 2018 Phase III IMpower131 study showed Roche’s TECENTRIQ (atezolizumab) plus chemotherapy (carboplatin and Abraxane) reduced the risk of disease worsening or death in the initial treatment of people with a type of advanced squamous lung cancer Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMpower131 study met its... Read more

March 14, 2018 Uncategorized

Save the date: Roche Analyst Event at ASCO 2018

Basel, 14 March 2018 Save the date: Roche Analyst Event at ASCO 2018 Monday, 4 June 2018 We are pleased to invite you to an analyst briefing to discuss data presented on the Roche Group’s oncology products and pipeline at the American Society of Clinical Oncology Annual Meeting (ASCO) in Chicago (1 – 5 June... Read more

March 8, 2018 Uncategorized

Changes to the Roche Enlarged Corporate Executive Committee

Basel, 08 March 2018 Changes to the Roche Enlarged Corporate Executive Committee Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that John C. Reed (1958), MD, PhD, Head of Roche Pharma Research and Early Development (pRED) since 2013, has decided to leave Roche for personal reasons and will return to the United States effective 2... Read more

March 8, 2018 PR/Corporate

Changes to the Roche Enlarged Corporate Executive Committee

Basel, 08 March 2018 Changes to the Roche Enlarged Corporate Executive Committee Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that John C. Reed (1958), MD, PhD, Head of Roche Pharma Research and Early Development (pRED) since 2013, has decided to leave Roche for personal reasons and will return to the United States effective 2... Read more

February 27, 2018 Uncategorized

European Commission approves Roche's Hemlibra for people with haemophilia A with inhibitors

Basel, 27 February 2018 European Commission approves Roche’s Hemlibra for people with haemophilia A with inhibitors First new medicine in over 20 years to treat people with haemophilia A with inhibitors in Europe Hemlibra demonstrated superior efficacy compared to prior treatment with bypassing agents in two phase III studies in adults, adolescents and children Once-weekly... Read more

February 27, 2018 Uncategorized

European Commission approves Roche's Hemlibra for people with haemophilia A with inhibitors

Basel, 27 February 2018 European Commission approves Roche’s Hemlibra for people with haemophilia A with inhibitors First new medicine in over 20 years to treat people with haemophilia A with inhibitors in Europe Hemlibra demonstrated superior efficacy compared to prior treatment with bypassing agents in two phase III studies in adults, adolescents and children Once-weekly... Read more